COMMUNIQUÉS West-GlobeNewswire

HealthBegins Launches Online Learning Platform to Scale ‘Upstreamist’ Movement with Expert-Led Instruction and Resources
28/07/2026
HealthBegins Academy combines expert instruction, applied frameworks and flexible learning formats to turn health equity strategies into sustainable, scalable practices PASADENA, Calif., July 28, 2026 (GLOBE NEWSWIRE [...]
Codexis to Report Second Quarter 2026 Financial Results on August 11
28/07/2026
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it [...]
New Pharmacoeconomic Analysis Finds KYZATREX® Could Cut the VA’s Total Cost of Testosterone Care by Nearly Half for America’s Veterans
28/07/2026
Model projects up to $16.2 million in potential annual savings for every 50,000 veterans transitioned from office-administered injectable therapy — while expanding treatment choice RALEIGH, N.C., July 28, 2026 (GLOBE [...]
Dandy Partners with Yeshiva University's New College of Dental Medicine to Power the Future of Digital Dentistry Education
28/07/2026
The first new dental school in NYC in over a century will run exclusively on Dandy's technology NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Dandy, the fully digital dental lab, today announced a partnership with Yeshiva [...]
Exagen Inc. to Participate in Upcoming Investor Conference
28/07/2026
CARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conference: Canaccord [...]
BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit
28/07/2026
Meetings in Shanghai and Changzhou link VitaGuard's commercial use in China with BioNexus' Southeast Asian plans and Fidelion's international licensing efforts KUALA LUMPUR, Malaysia, July 28, 2026 (GLOBE NEWSWIRE) -- [...]
BiomX And Water.IO Agree To Updated Zorronet Acquisition Terms
28/07/2026
Revised agreement provides BiomX with additional flexibility to support Zorronet while further aligning BiomX and Water IO around Zorronet's long-term success NETANYA, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- BiomX Inc [...]
STRATA Skin Sciences Appoints Medical Device Commercial Leader Erica Jordan as Chief Executive Officer
28/07/2026
Medical device veteran poised to lead STRATA to market leadership and continued revenue growth as Company continues next development phase HORSHAM, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“ [...]
Leap Distributors Levels Up: Names Dave Ascani CFO
28/07/2026
Financial Management Veteran Says He’s Excited to Join ‘Rock Stars of Medical Device Distribution’ DALLAS, July 28, 2026 (GLOBE NEWSWIRE) -- Leap Distributors has named Dave Ascani chief financial officer (CFO). As CFO [...]
Applied Biologics Expands National Commercial Payer Engagement Strategy for XWRAP®
28/07/2026
SCOTTSDALE, Ariz., July 28, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced the [...]
Colorectal Cancer Doesn’t Care How Young You Are
28/07/2026
Alliance’s Never Too Young Taskforce Tackles Growing Crisis as Cases of the Deadliest Cancer Continue to Rise in People Under 50 Key Takeaways: This August, World Cancer Support Month, the Colorectal Cancer Alliance ( [...]
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
28/07/2026
No ARIA-E observed across all genotypes, including APOE4 homozygotes ARIA-H tracking background rates Early biomarker movement consistent with target engagement 12-month topline results expected in Q1 2027 Cambridge, [...]
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
28/07/2026
LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
28/07/2026
Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial Important secondary endpoints were also met, including two-level [...]
NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026
28/07/2026
CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and [...]
Antag Therapeutics Announces Dosing of First Patient in Phase 2a Trial of First-in-Class GIPR Antagonist AT7687
28/07/2026
The Phase 2a study will evaluate AT7687 as a differentiated combination treatment approach for people living with obesity and type 2 diabetes A 13-week study of 150 randomized participants receiving either once-weekly [...]
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
28/07/2026
Second quarter revenue of $204 million, a year-over-year increase of 12% as reported and 13% organic GAAP operating income increased 1% year-over-year while adjusted operating income increased 55% Raising both FY26 [...]
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
28/07/2026
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second [...]
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
28/07/2026
Bemnifosbuvir/Ruzasvir (BEM/RZR) Achieved its Primary Endpoint of Statistical Non-inferiority Compared to Sofosbuvir/Velpatasvir (SOF/VEL; Epclusa ® ), a Standard-of-Care, in First-Ever Successful Head-to-Head Trial in [...]

Pages